Literature DB >> 12189465

Vasculitis induced by zafirlukast therapy.

M Soy1, H Ozer, A Canataroglu, D Gumurdulu, E Erken.   

Abstract

Zafirlukast is a leukotriene inhibitor that has recently been approved for the prophylaxis of asthma. Although this new product has been well accepted because of its convenient dosing and relatively few side effects, several cases of Churg-Strauss syndrome have been reported to be associated with its use. In this paper we describe the case of a 54-year-old white man with no history of corticosteroid therapy in whom leukocytoclastic vasculitis, hepatitis and eosinophilia developed while he was on zafirlukast therapy for mild asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12189465     DOI: 10.1007/s100670200086

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  3 in total

Review 1.  Important elements for the diagnosis of drug-induced liver injury.

Authors:  Vijay K Agarwal; John G McHutchison; Jay H Hoofnagle
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-17       Impact factor: 11.382

2.  A case of Churg-Strauss syndrome associated with antiphospholipid antibodies.

Authors:  Katalin Ferenczi; Timothy Chang; Melissa Camouse; Rujing Han; Robert Stern; Joseph Willis; Kevin D Cooper; Anita C Gilliam
Journal:  J Am Acad Dermatol       Date:  2006-12-18       Impact factor: 11.527

3.  Churg-Strauss syndrome (CSS) in a patient receiving pranlukast.

Authors:  Shigeto Kobayashi; Shyugo Ishizuka; Naoto Tamura; Makiyo Takaya; Kazuhiko Kaneda; Hiroshi Hashimoto
Journal:  Clin Rheumatol       Date:  2003-11-04       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.